Amarantus Bioscience Holdings, Inc. · OTC:AMBS

Amarantus Bioscience — NIO Helsinki 2nd Annual European Partnering & Investing Conference 2013

11 slides from Amarantus Bioscience's conference presentation, Sep 9, 2013

  1. Slide 1: Developing diagnostic and therapeutic products for neurological and apoptosis-related conditions

    1 Developing diagnostic and therapeutic products for neurological and apoptosis - related conditions. OTC/QB: AMBS September 2013: NIO Helsinki 2 nd Annual European Partnering & Investing Conference Amarantus - NIO Sept. 2013 1

  2. Slide 2: Amarantus Bioscience Holdings (AMBS)

    Amarantus Bioscience Holdings (AMBS) AMBS = public biotech company based in the Bay Area Amarantus - NIO Sept. 2013 2 AMBS Therapeutics Diagnostics

  3. Slide 3: The Cell Cycle & Alzheimer's Disease

    THE CELL CYCLE & ALZHEIMER'S DISEASE

  4. Slide 4: Cell Cycle Regulation & Alzheimer's

    C ell C ycle R egulation & Alzheimer’s • Cell Cycle: brain lacks all machinery • Cell Cycle Response to life and aging: triggered to re - enter the cell cycle • Hypothesis: AD patients lack proper cell cycle regulatory machinery, leading to aberrant processing (healthy normal get kicked out of cycle

  5. Slide 5: How to Assess CCR in Neurons

    How to Assess CCR in Neurons 1. Strategy: measure the cellular regulatory machinery in mononuclear cells purified from whole blood (peripheral blood lymphocytes or PBLs) as a surrogate for the cellular regulatory machinery in the brain 2. Collect whole blood from a subject and purify the lymphocytes

  6. Slide 6: Clinical Utility of Cell Cycle Dysregulation

    Clinical Utility of Cell Cycle Dysregulation Pioneering work from U. Leipzig *: • Dr. Thomas Arendt • Dr. Jan Steiler  Lymphocytes also show cell cycle dysregulation in AD patients  Lym phocyte Pro liferation Test ( LymPro Test®) for Alzheimer’s disease is based on this pioneering work Result: App

  7. Slide 7: Replication of LymPro Findings in 2012

    Replication of LymPro Findings in 2012 Steiler et al 2012 * Figure 1 . “Box - and - Whiskers Plot of self - normalized CD69 expression of B cells (CD19) in response to PWM mitogenic stimulation. Response to mitogenic stimulation was suppressed in AD subjects compared with either [Parkinson’s disease

  8. Slide 8: Further evidence in support of CCR: lymphocyte response to Rapamycin

    Further evidence in support of CCR: lymphocyte response to Rapamycin Tx Statistical analysis of the cell cycle distributions of lymphocytes from mild - AD, severe - AD and non - AD subjects . ** p< 0 . 01 vs non - AD cells . Amarantus - NIO Sept. 2013 8 Link to mTOR pathways?

  9. Slide 9: Patient Selection * CDx in AD Trials

    Patient Selection * CDx in AD Trials LymPro is being developed by Amarantus to identify which cognitively impaired (prodromal, MCI) patients will advance to dementia of the AD type • Distinguishing “progressors” from “non - progressors” is highly valuable as that is believed to be the best patient -

  10. Slide 10: Amarantus' LymPro Development Plan

    Amarantus’ LymPro Development Plan • Licensed LymPro from Provista Life Sciences in December 2012 • Becton Dickinson (BD) Biosciences in serving as the GLP Reference Lab for the assay development and clinical trials • DEVELOPMENT PLAN TO FDA APPROVAL – Q3/2013 – Complete Feasibility Studies to estab

  11. Slide 11: Thank you!

    11 Thank you! OTC/QB: AMBS Gerald E. Commissiong President & CEO Gerald@Amarantus.com 408 - 737 - 2734 x 102 www.amarantus.com Amarantus - NIO Sept. 2013 11

Amarantus Bioscience Holdings — NIO Helsinki 2nd Annual European Partnering & Investing Conference 2013 on 6ix